Massachusetts General Hospital (MGH; Boston, MA, USA) researchers--along with collaborators from Massachusetts Institute of Technology (MIT; Cambridge, MA, USA) and Alnylam Pharmaceuticals (Cambridge, MA, USA)--have found a way to block, in an animal model, the damaging inflammation that contributes to many disorders. In their report, published online October 2011 in the journal Nature Biotechnology, the investigators described utilizing small interfering RNA technology to silence the biochemical signals that attract a specific group of inflammatory cells to regions of tissue damage.

“The white blood cells known as monocytes play a critical role in the early stages of the immune response,” said Matthias Nahrendorf, MD, PhD, of the MGH Center for Systems Biology, the article’s senior author. “We now know there are two subsets of monocytes--an inflammatory subset that defends against pathogens and a reparative subset that supports healing. But if the inflammatory response is excessive, it can block the healing process and exacerbate conditions such heart disease and cancer.”

Cells damaged by injury or disease release cytokines that attract immune cells to the site of the damage. Inflammatory monocytes are guided to sites of tissue injury by a receptor protein called CCR2 (chemokine [C-C motif)] receptor 2), and the MGH-led team devised an approach targeting that molecule to block the inflammatory process but not the action of the reparative monocytes.

Small interfering RNA (siRNA) technology prevents production of specific proteins by binding to associated messenger RNA molecules and preventing their translation. Because the technique requires extreme precision in developing the right siRNA molecule and delivering it to the correct cellular location, the MGH team collaborated with Alnylam scientists who are experts in RNA-interference-based therapeutics and with MIT investigators Robert Langer, ScD, and Daniel Anderson, PhD, who have developed a nanoparticle-based system for delivering molecules to specific cellular compartments.

To make certain that their siRNA preparation targeted the right monocytes, the investigators first validated that its use reduced levels of CCR2 in monocytes and increased levels of the fragments produced when siRNA binds to its target. They then showed that monocytes from mice treated with the siRNA preparation were unable to migrate towards CCR2’s typical molecular target. Experiments in animal models of several important diseases showed that the siRNA preparation reduced the amount of cardiac muscle damaged by a heart attack, reduced the size and the number of inflammatory cells in atherosclerotic plaques and in lymphomas, and improved the survival of transplanted pancreatic islets.

“These inflammatory monocytes are involved in almost every major disease,” Dr. Nahrendorf explained. “Anti-inflammatory drugs currently on the market hit every inflammatory cell in the body, which can produce unwanted side effects. This new siRNA treatment doesn’t affect inflammatory cells that don’t rely on the CCCR2 receptor. That makes a big difference.” Dr. Nahrendorf is an assistant professor of radiology at Harvard Medical School (Boston, MA, USA).

Related Links:
Massachusetts General Hospital
Massachusetts Institute of Technology
Alnylam Pharmaceuticals